Tenaya Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Tenaya Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($20.28M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($23.28M) | Aug 6, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($23.28M) | Nov 10, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($26.86M) | May 7, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($26.86M) | Aug 6, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($26.86M) | Nov 10, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($25.63M) | Nov 10, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($29.43M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($29.43M) | Aug 6, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($32.23M) | Nov 10, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($32.23M) | May 7, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($32.23M) | Aug 6, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($29.14M) | Nov 6, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($33.27M) | Aug 8, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($33.27M) | Nov 6, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($31.74M) | Nov 6, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($31.74M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($31.74M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($30.70M) | Nov 8, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($28.40M) | Nov 8, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($20.94M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($24.08M) | Aug 6, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($27.54M) | May 7, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($26.71M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($30.82M) | Aug 6, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($33.76M) | May 7, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($30.92M) | Nov 6, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($35.10M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($33.72M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($31.30M) | Nov 8, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($28.62M) | Aug 9, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($31.15M) | May 10, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($18.30M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($15.24M) | Aug 10, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($13.11M) | May 11, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($10.45M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($8.87M) | Sep 8, 2021 |